Finch Therapeutics to Participate in Upcoming Investor Conferences
November 11 2021 - 7:00AM
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”)
(Nasdaq: FNCH), a clinical-stage microbiome therapeutics company
leveraging its Human-First Discovery® platform to develop a novel
class of orally administered biological drugs, today announced that
Mark Smith, PhD, Chief Executive Officer, will participate
virtually in two upcoming investor conferences:
- Jefferies London Healthcare
Conference: Finch will participate in a pre-recorded fireside chat
that will be available beginning on Thursday, November 18,
2021 at 3:00 am ET.
- Evercore ISI 4th Annual HealthCONx
Conference: Finch will participate in a fireside chat on Thursday,
December 2, 2021 at 10:05 am ET.
Webcasts of both fireside chats will be available under the
‘Investors & News’ section of the Finch website and will be
archived for approximately 30 days.
About Finch Therapeutics
Finch Therapeutics is a clinical-stage microbiome
therapeutics company leveraging its Human-First
Discovery® platform to develop a novel class of orally
administered biological drugs. With the capabilities to develop
both complete and targeted microbiome therapeutics, Finch is
advancing a rich pipeline of candidates designed to address a wide
range of unmet medical needs. Finch’s lead candidate, CP101, is in
late-stage clinical development for the prevention of
recurrent C. difficile infection (CDI), and has received
Breakthrough Therapy and Fast Track designations from the U.S. Food
and Drug Administration. In June 2020, Finch announced that CP101
met its primary efficacy endpoint in PRISM3, the first of two
pivotal trials to support the development of CP101 for the
prevention of recurrent CDI. PRISM4, a Phase 3 trial, is designed
to serve as the second pivotal trial of CP101 for recurrent CDI.
Finch is also developing CP101 for the treatment of chronic
hepatitis B virus, and FIN-211 for the treatment of the
gastrointestinal and behavioral symptoms of autism spectrum
disorder. Finch has a partnership with Takeda focused on the
development of targeted microbiome therapeutics for inflammatory
bowel disease.
Human-First Discovery® is a registered trademark of Finch
Therapeutics Group, Inc.
Investor Contact:
Laurence WattsGilmartin Group(619)
916-7620laurence@gilmartinir.com
or
Stephen JasperGilmartin Group(858)
525-2047stephen@gilmartinir.com
Media Contact:
Jenna UrbanBerry & Company Public
Relationsjurban@berrypr.com212-253-8881
Finch Therapeutics (NASDAQ:FNCH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Finch Therapeutics (NASDAQ:FNCH)
Historical Stock Chart
From Jul 2023 to Jul 2024